查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1864054

细胞收集市场按应用、产品类型、细胞类型和最终用户划分 - 全球预测 2025-2032

Cell Harvesting Market by Application, Product Type, Cell Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，细胞收集市场将成长至 48.4 亿美元，复合年增长率为 9.50%。

关键市场统计数据
基准年 2024 23.4亿美元
预计年份：2025年 25.6亿美元
预测年份 2032 48.4亿美元
复合年增长率 (%) 9.50%

不断发展的收穫技术和整合过程控制正在重新定义研究和治疗药物生产环境中的操作标准

细胞收穫是现代生命科学工作流程的核心，也是生物样本与下游製程（从治疗药物生产到高解析度诊断）之间的关键环节。酶解离、机械提取和抗体筛选技术的进步，使这项技术从手工操作发展成为强调无菌性、可重复性和高通量的整合自动化工作流程。随着实验室从药物发现扩展到生产，细胞收穫通讯协定的要求也在不断变化，需要更严格的製程控制、可追溯性以及与细胞製品监管框架的兼容性。

营运需求迫使研究实验室重新评估上游培养条件与收穫参数的匹配度。细胞扩增阶段的培养基成分、生物反应器动力学和收穫触发点都会影响细胞活力、表型保真度和下游产量。因此，细胞培养科学家、製程工程师和品管专家之间的跨职能合作已成为优化收穫策略的关键。尤其是在细胞治疗和再生医学领域，人们对产品一致性的期望日益提高，这凸显了检验的收穫标准操作规程 (SOP) 的必要性，这些规程应考虑细胞类型异质性、对酶处理的敏感性以及潜在的压力诱导表型漂移。

自动化、单细胞精确度和监管要求的融合正在推动收穫方法朝向整合化、数据驱动的製程架构演进。

在技​​术创新、法规演变以及治疗和诊断需求模式变化的推动下，细胞采集领域正在发生多项变革。自动化和封闭式采集解决方案正从试点实验室走向常规应用，在提高通量的同时，降低了污染风险，并提升了实验的可重复性。单细胞技术和微流体平台为更精确地分离和保存稀有细胞群提供了新的机会，这正在重塑生物标记发现和个人化倡议的研究设计。

同时，细胞采集流程与下游分析和处理环节的整合已成为显着趋势。线上活力评估、自动化细胞计数器和快速无菌检测技术能够即时确定采集终点，并进行自适应处理以优化产量和品质。酶学和微创分离试剂的进步使得在最大限度减少功能损失的情况下采集敏感的原代细胞和干细胞成为可能。此外，仪器製造商、试剂供应商和终端用户之间的合​​作加速了即插即用模组的开发，这些模组整合了采集、冷冻保存和细胞库构建的工作流程，从而缩短了流程并减少了人工干预。

从监管角度来看，对文件记录、物料可追溯性和製程验证的更严格要求正在推动数位化批次记录和分析主导製程控制的普及。总而言之，这些趋势预示着未来样本收集不再是孤立的步骤，而是会演变为细胞生命週期中一个整合的、数据丰富的阶段，从而支持下游治疗效果和诊断可靠性。

关税驱动的采购结构调整和区域筹资策略将重建电池收集供应链的韧性和业务连续性

近期关税政策对实验室和製造商的采购惯例、供应链结构以及总成本考量产生了显着的连锁反应。进口实验室设备和试剂关税的征收推高了资本设备和专用耗材的成本，迫使许多机构重新评估其供应商组合和总到岸成本，而不只关注单位成本。为此，采购团队正在加强供应商资质审核流程，协商长期合约以稳定价格，并与财务部门合作，模拟多年营运影响。

情势的变化加速了关键零件和试剂本地采购及近岸外包的讨论。製造商和经销商正在探索替代生产基地和双重采购策略，以降低关税带来的成本上行风险。这项变更也影响前置作业时间和库存管理，各组织纷纷维持关键试剂和耗材的策略性缓衝库存，以避免供应中断，同时增加对需求预测能力的投入，以降低库存过剩的风险。

关税也在推动采购结构的创新，基于服务的模式和试剂即服务模式正日益普及，因为它们减轻了终端用户的部分资金负担和贸易政策波动风险。对于仪器製造商而言，关税压力正在加速本地化设计进程，减少对进口零件的依赖，并使其更容易适应不断变化的贸易要求。在可行的情况下，将生产转移到本地组装厂可以降低成本并缩短供应链，但这同时也需要对本地製造能力和品质保证进行投资。

最后，关税变化带来的累积效应凸显了政策监测和情境规划对于细胞采集工作流程中相关人员的重要性。那些积极评估关税趋势并将政策敏感性纳入筹资策略的企业，将更有利于在持续投资创新的同时，保持业务永续营运和获利能力。

详细的細項分析揭示了应用需求、产品类型、细胞类别和最终用户优先顺序如何共同决定收穫通讯协定和采购选择。

细分市场分析表明，细胞采集市场与不同的应用领域相交融，每个领域都有其独特的製程、监管和品质要求。应用范围涵盖生物银行服务和采用冷冻保存通讯协定的细胞库；诊断领域，包括流式细胞技术和分子诊断；药物发现和开发，涵盖生物标记发现、临床前筛检和毒性测试；以及再生医学，包括细胞治疗和组织工程。每种应用对采集时间、细胞处理和储存培养基的选择都有独特的限制，因此需要客製化的采集通讯协定，既要保留目标特性，也要确保与下游製程相容。

在产品方面，耗材/试剂与设备/装置之间的差异决定了采购和操作流程。耗材/试剂，例如缓衝液、培养基和酶，决定了细胞释放和储存的生化环境；而设备，例如自动细胞计数器、生物反应器和离心机，则决定了通量和物理操作参数。试剂的化学性质与设备的机械性能之间的相互作用通常决定了最佳的细胞收集技术；脆弱的干细胞可能需要温和的酶製剂，而永生化细胞株则可能受益于更强力的离心通讯协定。

细胞类型在决定细胞收集策略方面也起着关键作用。虽然像CHO、HEK293和HeLa这样的细胞株相对稳定，可以使用标准化方法进行操作，但免疫细胞（如B细胞和T细胞）、原代细胞（如造血间质干细胞细胞、间质干细胞和外周血单核细胞）则更为敏感且异质性更高，需要更温和的分离和分选方法。干细胞，无论是胚胎干细胞或诱导多功能，都需要极其精细的操作才能维持其多功能和分化潜能，这会影响试剂的选择和收集后的处理。

包括学术研究机构、生物技术公司、製药公司、合约研究组织 (CRO)、医院和临床实验室在内的终端用户，各自有着不同的优先事项。学术机构优先考虑灵活性和实验的多样性，而生物技术公司和製药公司则重视可扩展性和法规遵循。 CRO 专注于满足不同客户需求的标准化、可重复的工作流程，而临床实验室则优先考虑快速交付检测结果和患者导向的品质标准。了解这些细分领域对于设计能够将技术能力与终端使用者期望相符的采集解决方案至关重要。

区域创新生态系统、监管多样性和製造能力如何影响全球收穫技术的应用和供应策略

区域趋势将在影响收穫技术的应用、监管和商业化方面发挥关键作用。在美洲，强大的创新生态系统以及生物技术和生物製药活动的集中，推动了自动化和整合式收穫解决方案的早期应用，而成熟的製造群则支援本地化的组装和试剂生产。这种环境促进了仪器製造商、试剂供应商和临床开发人员之间的合作，共同开发满足监管和高处理容量要求的工作流程。

欧洲、中东和非洲地区呈现出多元化的格局，部分市场拥有严格的法规结构和高标准的临床规范，而另一些市场则正在积极推动能力倡议。欧洲卓越中心通常在采用以检验主导的细胞采集方法和封闭式系统流程进行临床细胞治疗方面发挥着主导作用，同时，区域伙伴关係和技术转移项目也支持邻近市场的产能扩张，重点在于协调培训、品质系统和供应链，以减少不同司法管辖区之间的差异。

亚太地区正经历快速扩张和本土製造能力提升的双重趋势，这主要得益于对细胞疗法研发和诊断技术的巨额投资。该地区各市场正积极投资于本地试剂生产、设备製造和劳动力发展，以满足国内需求并掌握出口机会。各国法规环境的差异要求跨国公司精心製定市场准入和合规策略，在关键环节的集中化与本地伙伴关係之间取得平衡，从而优化可及性和应对力。

试剂创新、模组化自动化、策略合作以及检验的封闭式系统工作流程，是推动竞争优势和供应商差异化的关键因素。

在整个采样生态系统中，各产业参与者正透过创新、策略伙伴关係和垂直整合来巩固自身地位。耗材和试剂供应商致力于开发更温和的解离化学方法、更稳定的储存方案以及品管测试的培养基，以降低采集后样本性能的差异性。仪器製造商则优先考虑模组化自动化、与实验室资讯管理系统的互通性以及小型化，以支援科学研究和临床应用。

试剂供应商和仪器供应商之间的策略联盟日益普遍，从而能够提供捆绑式解决方案，简化检验并缩短终端用户的整合时间。合约研究和生产组织 (CRO) 透过服务能力实现差异化，包括检验的采集通讯协定、低温运输物流和样本可追溯性。专注于单细胞分离、微流体和随线分析的新兴参与企业，正透过提供精准的工具挑战现有企业，这些工具在诊断和个人化治疗领域开闢了新的应用场景。

竞争格局也受到专有试剂、软体驱动的製程控制和检验的封闭式系统工作流程等智慧财产权的影响。能够将强大的供应链、法规知识和售后支援相结合的公司，更有可能赢得与临床开发商和商业製造商的长期合约。同时，客户越来越期望获得关于试剂性能和仪器可靠性的透明数据，这促使供应商发布检验研究，并提供持续的培训和技术支持，从而降低准入门槛。

为领导者提供切实可行的策略，以增强供应链韧性、加速自动化应用，并使收割流程符合监管和规模需求。

产业领导者应优先考虑几项策略性倡议，以维持业务连续性、促进创新并降低营运风险。首先，供应商网路多元化以及关键试剂和仪器组件的双重采购协议，将有助于降低贸易政策变化和单一供应来源中断的影响。此外，制定兼顾准时制原则和关键物料安全库存的战略库存政策，既能保护营运免受短期供应波动的影响，又能避免不必要的资金占用。

其次，对自动化和封闭式采收系统解决方案的投资能够带来显着的回报，例如提高可重复性、应对力和劳动效率。企业领导者应重视自动化，不仅将其视为节约成本的措施，更应将其视为流程标准化的基础，从而支持规模化生产和监管合规。这些投资应与数位化过程控制和电子批次记录相结合，以确保可追溯性并便于审核。

第三，与试剂和设备供应商建立伙伴关係，共同验证针对特定细胞类型和应用的客製化工作流程。共同检验可以缩短实施时间，并确保收穫流程符合下游分析和生产要求。如果关税或供应限制构成风险因素，可考虑与当地合作伙伴进行本地组装和试剂定制，以缩短前置作业时间并降低到岸成本。

第四，我们将透过员工培训计画提升内部能力，重点培养无菌操作技术、资料素养以及生物学家和工程师之间的跨学科理解。强化训练将减少人为错误，并增强组织采用新型采集技术的能力。最后，我们将优先与监管机构和标准组织积极合作，制定能够识别不同细胞类型和治疗方法特性的实用检验方法。这将有助于加快新型采集方法核准途径的明确化。

一种结合文献综述、专家访谈、产品检验分析和多维细分的调查方法，旨在得出切实可行的收穫洞察。

本分析所依据的研究结合了对科学文献、技术白皮书和监管指南的系统性回顾，以及来自学术界、工业界和临床领域的专家和经验丰富的从业人员的定性见解。结构化的提取流程捕捉了与不同细胞类型和应用相关的创新方法、检验方法和常见操作挑战。技术产品规格和同行评审的性能数据评估了仪器的性能，而试剂配方研究则提供了与敏感细胞群兼容性的背景资讯。

主要研究包括对实验室主任、製程开发科学家、采购人员和品质保证专业人员的访谈，以检验观察到的趋势并确定实际限制因素，例如前置作业时间、验证时间表和人员技能差距。该研究采用三角测量法，将专家见解与公开的监管文件和技术资料表进行交叉比对，以确保一致性并识别差距。研究采用细分方法分析了收穫策略对以下方面的影响：- 应用领域（细胞库、诊断、药物发现、再生医学）- 产品类型（耗材/试剂与仪器）- 细胞类别（细胞株、​​免疫细胞、原代细胞、干细胞）- 最终用户（学术机构、生物技术/製药公司、合约研究组织、临床实验室）。

限制包括各地区监管协调程度的差异以及贸易政策的流动性，这些都可能改变采购趋势。在实证定量资料集不完整的情况下，对潜在操作影响的解读是基于定性综合和专家共识。所有主要研究均强调伦理考量和遵守研究诚信的最佳实践，并透过多位专家审查检验研究结果，以最大程度地减少偏差。

整合技术、供应链和监管方面的必要因素，为科学研究和临床领域的细胞采集制定策略路径

适应不断变化的细胞采集需求需要采取综合办法，整合技术能力、供应链适应性和监管前瞻性。自动化、单细胞分离和随线分析技术的成熟为提高可重复性和将製程规模从实验室扩展到临床生产提供了清晰的路径。同时，关税带来的日益增长的采购压力凸显了多元化采购、尽可能在地化以及采用能够降低贸易政策波动风险的采购模式的策略必要性。

从市场区隔的角度来看，显然一刀切的方法是行不通的。针对每种应用、产品类型、细胞生物学特性以及最终用户需求，都需要製定兼顾产量、表型保持和与下游製程相容性的收穫策略。不同地区在法规结构和生产能力方面的差异，进一步凸显了市场特定策略的必要性，该策略需充分考虑当地的实际情况和限制。最终，那些投资于检验的自动化工作流程、建立强大的供应商生态系统并培养跨职能能力的企业，将更有能力将卓越的收穫技术转化为在研究、诊断和治疗领域的竞争优势。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 为提高无菌性和可重复性，封闭式自动化细胞收集系统的应用日益广泛
  • 透过人工智慧和机器人技术的融合，实现高通量细胞分离和处理技术
  • 开发一次性微流体平台：实现温和且扩充性的干细胞分离工作流程
  • 连续灌注采集技术的进步将支持大规模生物製造需求
  • 标准化的细胞活力评估通讯协定对于确保细胞治疗产品品质的一致性至关重要。
  • 经济高效的培养基回收与永续的细胞收穫操作耗材创新
  • 封闭系统验证的法规遵循性，以降低细胞治疗生产中的污染风险
  • 推广自动化温和离心技术，以提高收穫时的产量和细胞完整性

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 细胞收集市场：依应用划分

  • 细胞库
    • 生物银行服务
    • 冷冻保存
  • 诊断
    • 流式细胞技术
    • 分子诊断
  • 药物发现与开发
    • 生物标记发现
    • 临床前筛检
    • 毒理学研究
  • 再生医学
    • 细胞疗法
    • 组织工程

9. 按产品类型分類的细胞收集市场

  • 耗材和试剂
    • 缓衝液/溶液
    • 培养基
    • 酵素
  • 设备/器材
    • 自动细胞计数器
    • 生物反应器
    • 离心机

第十章：以细胞类型分類的细胞收集市场

  • 细胞株
    • CHO细胞
    • HEK293细胞
    • HeLa细胞
  • 免疫细胞
    • B细胞
    • T细胞
  • 原代细胞
    • 造血干细胞
    • 间质干细胞
    • 週边血单核细胞
  • 干细胞
    • 胚胎干细胞
    • 诱导性多功能干细胞

第十一章 依最终用户分類的细胞收集市场

  • 学术和研究机构
  • 生物技术和製药公司
  • CRO（受託研究机构）
  • 医院和临床实验室

第十二章 各地区的细胞采集市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 细胞收集市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国细胞采集市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Sartorius AG
    • Lonza Group AG
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • Terumo Corporation
    • Miltenyi Biotec GmbH
    • STEMCELL Technologies Inc.
Product Code: MRR-007C484E5E61

The Cell Harvesting Market is projected to grow by USD 4.84 billion at a CAGR of 9.50% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.34 billion
Estimated Year [2025] USD 2.56 billion
Forecast Year [2032] USD 4.84 billion
CAGR (%) 9.50%

How evolving harvesting practices and integrated process controls are redefining operational standards across research and therapeutic manufacturing environments

Cell harvesting lies at the heart of contemporary life sciences workflows, acting as the critical bridge between biological samples and downstream applications ranging from therapeutic manufacturing to high-resolution diagnostics. Advances in enzymatic dissociation, mechanical extraction, and antibody-based selection techniques have evolved the practice from manual bench operations to integrated, automated workflows that emphasize sterility, reproducibility, and throughput. As laboratories scale from discovery to production, the demands placed on harvesting protocols have shifted, requiring tighter process control, traceability, and compatibility with regulatory frameworks governing cell-based products.

Operational imperatives have pushed laboratories to rethink the interface between upstream culture conditions and harvesting parameters. Decisions made during cell expansion-media composition, bioreactor dynamics, and harvest triggers-influence viability, phenotype fidelity, and downstream processing yields. Consequently, cross-functional collaboration between cell culture scientists, process engineers, and quality professionals has become central to optimizing harvest strategies. Rising expectations for product consistency, especially in cell therapy and regenerative medicine, have underscored the need for validated harvesting SOPs that account for cell type heterogeneity, sensitivity to enzymatic treatments, and the potential for stress-induced phenotypic drift.

Convergence of automation, single-cell precision, and regulatory expectations driving harvesting toward integrated, data-driven process architectures

The landscape of cell harvesting is undergoing several transformative shifts driven by technological innovation, regulatory evolution, and changing demand patterns across therapeutic and diagnostic sectors. Automation and closed-system harvesting solutions have moved from pilot labs into routine use, reducing contamination risk and improving reproducibility while enabling higher throughput. Single-cell technologies and microfluidic platforms have introduced new opportunities to isolate and preserve rare cell populations with much greater precision, which in turn is reshaping study designs in biomarker discovery and personalized medicine initiatives.

Concurrently, there is a pronounced shift toward integrating harvesting steps with downstream analytics and processing. In-line viability assessment, automated cell counters, and rapid sterility checks now inform real-time decisions about harvest endpoints, enabling adaptive processing that optimizes yield and quality. Advances in enzymology and gentle dissociation reagents have made it possible to harvest sensitive primary cells and stem cells with reduced loss of function. Moreover, collaborations between equipment manufacturers, reagent providers, and end-users have accelerated the development of plug-and-play modules that align harvesting with cryopreservation and banking workflows, thereby compressing timelines and reducing manual handling.

From a regulatory perspective, more rigorous expectations for documentation, material traceability, and process validation are encouraging adoption of digital batch records and analytics-driven process controls. These trends collectively point to a future where harvesting is less an isolated procedural step and more an integrated, data-rich phase of the cell lifecycle that supports downstream therapeutic efficacy and diagnostic reliability.

Tariff-driven procurement realignments and regional sourcing strategies reshaping supply chain resilience and operational continuity in cell harvesting

Recent tariff measures have generated pronounced ripple effects across procurement practices, supply chain configurations, and total cost considerations for laboratories and manufacturers. Tariffs applied to imported laboratory instruments and reagents have increased the cost of capital equipment and specialized consumables, prompting many organizations to reassess supplier portfolios and total landed cost rather than focusing solely on unit pricing. In response, procurement teams have intensified supplier qualification processes, negotiated longer-term agreements to stabilize pricing, and collaborated with finance to model multi-year operational impacts.

The tariff landscape has accelerated conversations about regional sourcing and nearshoring of critical components and reagents. Manufacturers and distributors have explored alternative production footprints and dual-sourcing strategies to mitigate the risk of tariff-driven cost escalations. This shift has implications for lead times and inventory practices: organizations are increasingly maintaining strategic buffer stocks of essential reagents and consumables to avoid disruption, while also investing in demand-planning capabilities that reduce the risk of overstocking.

Tariffs have also spurred innovation in procurement structures, where service-based models and reagent-as-a-service offerings gain appeal because they can shift some of the capital burden and exposure to trade policy variations away from end-users. For instrument makers, tariff pressures have catalyzed design-for-localization efforts that reduce reliance on imported subcomponents and facilitate compliance with changing trade requirements. Transitioning to locally assembled equipment, where feasible, helps dampen the cost impact and shortens supply chains, but it also requires investment in local manufacturing capabilities and quality assurance frameworks.

Finally, the cumulative effect of tariff changes has heightened the importance of policy monitoring and scenario planning for stakeholders in cell harvesting workflows. Organizations that proactively assess tariff trajectories and incorporate policy sensitivity into sourcing strategies are better positioned to maintain continuity of operations and preserve margins while continuing to invest in innovation.

Detailed segmentation reveals how application needs, product types, cell categories, and end-user priorities converge to dictate harvesting protocols and procurement choices

Segmentation analyses reveal that the harvesting market intersects distinct application areas each with specific process, regulatory, and quality priorities. Applications span cell banking with biobanking services and cryopreservation protocols, diagnostics that include flow cytometry and molecular diagnostics, drug discovery and development encompassing biomarker discovery, preclinical screening, and toxicology studies, and regenerative medicine covering cell therapy and tissue engineering. Each application imposes unique constraints on harvest timing, cell handling, and preservation media selection, requiring tailored harvesting protocols that preserve target attributes while ensuring downstream compatibility.

On the product front, differentiation between consumables and reagents versus instruments and equipment shapes procurement and operational workflows. Consumables and reagents such as buffers, culture media, and enzymes determine the biochemical milieu for cell release and preservation, while instruments like automated cell counters, bioreactors, and centrifuges define throughput capabilities and physical handling parameters. The interplay between reagent chemistry and instrument mechanics often dictates the optimal harvesting approach, as gentle enzymatic formulations may be required for fragile stem cells while robust centrifugation protocols may suit immortalized cell lines.

Cell type is another critical determinant of harvesting strategy. Cell lines such as CHO, HEK293, and HeLa offer relative robustness and standardized handling; immune cells including B and T cells and primary cells like hematopoietic and mesenchymal stem cells and peripheral blood mononuclear cells exhibit greater sensitivity and heterogeneity, demanding gentler dissociation and selection methods. Stem cells, whether embryonic or induced pluripotent, require the most delicate handling to maintain pluripotency and differentiation potential, influencing reagent selection and post-harvest handling.

End users including academic and research institutes, biotech and pharma companies, contract research organizations, and hospitals and clinical laboratories each balance different priorities. Academic settings often prioritize flexibility and experimental variety, whereas biotech and pharma prioritize scale-up readiness and regulatory compliance. Contract research organizations focus on standardized, reproducible workflows that support diverse client needs, and clinical labs emphasize turnaround time and patient-facing quality standards. Understanding these segmentation layers is essential for designing harvesting solutions that align technical capabilities with end-user expectations.

How regional innovation ecosystems, regulatory diversity, and manufacturing capacity differences influence harvesting adoption and supply strategies worldwide

Regional dynamics play a decisive role in shaping how harvesting technologies are adopted, regulated, and commercialized. In the Americas, a robust innovation ecosystem and concentration of biotech and biopharma activity drive early adoption of automation and integrated harvesting solutions, while established manufacturing clusters support localization of assembly and reagent production. This environment incentivizes collaboration between instrument makers, reagent suppliers, and clinical developers to co-develop workflows that meet regulatory expectations and high-throughput requirements.

Europe, the Middle East & Africa presents a heterogeneous landscape where stringent regulatory frameworks and high clinical standards in several markets coexist with emerging capacity-building initiatives in others. European centers of excellence often lead in validation-driven harvesting approaches and in adopting closed-system processes for clinical cell therapies. Meanwhile, regional partnerships and technology transfer programs support expansion of capacity in adjacent markets, with an emphasis on training, quality systems, and supply chain harmonization to reduce variability across jurisdictions.

Asia-Pacific reflects a mix of rapid scale-up and increasing domestic manufacturing capability, underpinned by significant investment in cell therapy development and diagnostics. Markets across the region are investing in local reagent production, instrument manufacturing, and workforce development to support both domestic demand and export opportunities. Diverse regulatory environments across countries in the region mean that multinational organizations must tailor market entry and compliance strategies carefully, balancing centralization of critical components with local partnerships to optimize access and responsiveness.

Competitive dynamics driven by reagent innovation, modular automation, strategic alliances, and validated closed-system workflows shaping vendor differentiation

Industry players operating across the harvesting ecosystem are pursuing a mix of innovation, strategic partnerships, and vertical integration to strengthen their positions. Companies supplying consumables and reagents concentrate on developing gentler dissociation chemistries, stabilized preservation solutions, and QC-tested media that reduce variability in post-harvest performance. Instrument manufacturers emphasize modular automation, interoperability with laboratory information management systems, and miniaturization to serve both research and clinical applications.

Strategic alliances between reagent providers and equipment vendors are becoming more common, enabling bundled solutions that simplify validation and reduce integration timelines for end-users. Contract research and manufacturing organizations are differentiating through service-level capabilities that include validated harvest protocols, cold-chain logistics, and sample traceability. Emerging entrants focused on single-cell isolation, microfluidics, and in-line analytics are challenging incumbents by offering precision tools that unlock new use cases in diagnostics and personalized therapies.

Competitive dynamics are also shaped by intellectual property around proprietary reagents, software-driven process controls, and validated closed-system workflows. Firms that can combine robust supply chains, regulatory know-how, and post-sale support are positioned to win long-term contracts with clinical developers and commercial manufacturers. At the same time, customers increasingly expect transparent data on reagent performance and instrument reliability, which incentivizes vendors to publish validation studies and to offer ongoing training and technical support that reduce adoption friction.

Actionable strategies for leaders to strengthen supply resilience, accelerate automation adoption, and align harvesting processes with regulatory and scale-up needs

Industry leaders should prioritize several strategic initiatives to preserve continuity, foster innovation, and reduce operational risk. First, diversifying supplier networks and establishing dual-sourcing agreements for critical reagents and instrument components mitigates exposure to trade policy shifts and single-source disruptions. Complementing this with a strategic inventory policy-balancing just-in-time principles with safety stocks for essential items-can protect operations from short-term supply volatility while avoiding unnecessary capital lock-up.

Second, investing in automation and closed-system harvesting solutions yields returns in reproducibility, compliance readiness, and labor efficiency. Leaders should evaluate automation not merely as cost reduction but as an enabler of process standardization that supports scale-up and regulatory compliance. These investments should be paired with digital process controls and electronic batch records to ensure traceability and to facilitate audits.

Third, develop partnerships with reagent and equipment vendors to co-validate workflows tailored to specific cell types and applications. Collaborative validation reduces time-to-deployment and ensures the harvesting process aligns with downstream analytical and manufacturing requirements. Where tariffs or supply constraints pose risks, explore localized assembly or reagent customization with regional partners to shorten lead times and reduce landed costs.

Fourth, build internal capabilities through workforce training programs that emphasize aseptic technique, data literacy, and cross-disciplinary understanding between biologists and engineers. Enhanced training reduces human error and strengthens the organization's ability to adopt new harvesting technologies. Finally, prioritize proactive engagement with regulators and standards bodies to shape pragmatic validation approaches that recognize the nuances of different cell types and therapeutic modalities, thereby accelerating pathway clarity for novel harvesting approaches.

Research methodology integrating literature synthesis, expert interviews, product validation analysis, and multi-dimensional segmentation to derive actionable harvesting insights

The research underpinning this analysis combined systematic review of scientific literature, technical whitepapers, and regulatory guidance with qualitative inputs from subject-matter experts and experienced practitioners across academia, industry, and clinical settings. A structured extraction process captured methodological innovations, validation approaches, and common operational challenges related to harvesting across different cell types and applications. Technical product specifications and peer-reviewed performance data informed the assessment of instrument capabilities, while reagent formulation studies provided context for compatibility considerations with sensitive cell populations.

Primary research included interviews with laboratory directors, process development scientists, procurement leads, and quality assurance professionals to validate observed trends and to surface practical constraints such as lead times, validation timelines, and workforce skill gaps. The study applied triangulation by cross-referencing expert insights with publicly available regulatory documents and technical datasheets to ensure consistency and to identify areas of divergence. Segmentation was applied to analyze the implications of harvesting strategies across applications (including banking, diagnostics, drug development, and regenerative medicine), product types (consumables and reagents versus instruments), cell categories (cell lines, immune cells, primary cells, and stem cells), and end users (academic, biotech and pharma, CROs, and clinical laboratories).

Limitations include variability in regional regulatory harmonization and the evolving nature of trade policies, which may alter procurement dynamics. Where empirical quantitative datasets were incomplete, qualitative synthesis and expert consensus guided the interpretation of likely operational impacts. Ethical considerations and adherence to best practices in research integrity informed all primary engagements, and findings were validated through multiple expert reviews to minimize bias.

Synthesis of technological, supply chain, and regulatory imperatives that define the strategic path forward for harvesting across research and clinical landscapes

Adapting to the evolving demands of cell harvesting requires a holistic approach that integrates technological capability, supply chain adaptability, and regulatory foresight. The maturation of automation, single-cell isolation, and in-line analytics presents clear pathways to improve reproducibility and to scale processes from benchtop experiments to clinical manufacturing. Simultaneously, tariff-driven procurement pressures highlight the strategic imperative to diversify sourcing, localize where feasible, and adopt procurement models that reduce exposure to trade policy fluctuations.

Segmentation considerations underscore that a one-size-fits-all approach is insufficient: applications, product types, cell biology, and end-user needs each require targeted harvesting strategies that balance yield, phenotype preservation, and downstream compatibility. Regional differences in regulatory frameworks and manufacturing capacity further necessitate market-specific approaches that account for local capabilities and constraints. Ultimately, organizations that invest in validated, automated workflows, cultivate resilient supplier ecosystems, and foster cross-functional capabilities will be best positioned to translate harvesting excellence into competitive advantage across research, diagnostics, and therapeutic domains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing adoption of closed and automated cell harvesting systems for improved sterility and reproducibility
  • 5.2. Integration of artificial intelligence and robotics for high throughput cell separation and processing
  • 5.3. Development of single-use microfluidic platforms for gentle and scalable stem cell isolation workflows
  • 5.4. Advancements in continuous perfusion harvesting techniques to support large scale biomanufacturing demands
  • 5.5. Rising emphasis on standardized viability assessment protocols to ensure consistent cell therapy product quality
  • 5.6. Innovations in cost effective media recycling and sustainable consumables for cell harvesting operations
  • 5.7. Regulatory alignment on closed system validations to reduce contamination risk in cell therapy manufacturing
  • 5.8. Expansion of automated gentle centrifugation technologies for enhanced yield and cell integrity during harvest

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell Harvesting Market, by Application

  • 8.1. Cell Banking
    • 8.1.1. Biobanking Services
    • 8.1.2. Cryopreservation
  • 8.2. Diagnostics
    • 8.2.1. Flow Cytometry
    • 8.2.2. Molecular Diagnostics
  • 8.3. Drug Discovery & Development
    • 8.3.1. Biomarker Discovery
    • 8.3.2. Preclinical Screening
    • 8.3.3. Toxicology Studies
  • 8.4. Regenerative Medicine
    • 8.4.1. Cell Therapy
    • 8.4.2. Tissue Engineering

9. Cell Harvesting Market, by Product Type

  • 9.1. Consumables & Reagents
    • 9.1.1. Buffers & Solutions
    • 9.1.2. Culture Media
    • 9.1.3. Enzymes
  • 9.2. Instruments & Equipment
    • 9.2.1. Automated Cell Counters
    • 9.2.2. Bioreactors
    • 9.2.3. Centrifuges

10. Cell Harvesting Market, by Cell Type

  • 10.1. Cell Lines
    • 10.1.1. CHO Cells
    • 10.1.2. HEK293 Cells
    • 10.1.3. HeLa Cells
  • 10.2. Immune Cells
    • 10.2.1. B Cells
    • 10.2.2. T Cells
  • 10.3. Primary Cells
    • 10.3.1. Hematopoietic Stem Cells
    • 10.3.2. Mesenchymal Stem Cells
    • 10.3.3. Peripheral Blood Mononuclear Cells
  • 10.4. Stem Cells
    • 10.4.1. Embryonic Stem Cells
    • 10.4.2. Induced Pluripotent Stem Cells

11. Cell Harvesting Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Biotech & Pharma Companies
  • 11.3. Contract Research Organizations
  • 11.4. Hospitals & Clinical Laboratories

12. Cell Harvesting Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cell Harvesting Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cell Harvesting Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Thermo Fisher Scientific Inc.
    • 15.3.2. Merck KGaA
    • 15.3.3. Danaher Corporation
    • 15.3.4. Sartorius AG
    • 15.3.5. Lonza Group AG
    • 15.3.6. Becton, Dickinson and Company
    • 15.3.7. Bio-Rad Laboratories, Inc.
    • 15.3.8. Terumo Corporation
    • 15.3.9. Miltenyi Biotec GmbH
    • 15.3.10. STEMCELL Technologies Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL HARVESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL HARVESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CELL HARVESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CELL HARVESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CELL HARVESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL HARVESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CELL HARVESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL HARVESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CELL HARVESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CELL HARVESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CELL HARVESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CELL HARVESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CELL HARVESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CELL HARVESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CELL HARVESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CELL HARVESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CELL HARVESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CELL HARVESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CELL HARVESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CELL HARVESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CELL HARVESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CELL HARVESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CELL HARVESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CELL HARVESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CELL HARVESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELL HARVESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELL HARVESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CELL HARVESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL HARVESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CELL HARVESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL BANKING, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL BANKING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL BANKING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL BANKING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL BANKING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL BANKING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL BANKING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOBANKING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOBANKING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOBANKING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOBANKING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOBANKING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOBANKING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL HARVESTING MARKET SIZE, BY CRYOPRESERVATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CELL HARVESTING MARKET SIZE, BY CRYOPRESERVATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL HARVESTING MARKET SIZE, BY CRYOPRESERVATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CELL HARVESTING MARKET SIZE, BY CRYOPRESERVATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL HARVESTING MARKET SIZE, BY CRYOPRESERVATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CELL HARVESTING MARKET SIZE, BY CRYOPRESERVATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL HARVESTING MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CELL HARVESTING MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL HARVESTING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CELL HARVESTING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL HARVESTING MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CELL HARVESTING MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL HARVESTING MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CELL HARVESTING MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL HARVESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CELL HARVESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL HARVESTING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CELL HARVESTING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL HARVESTING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CELL HARVESTING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL HARVESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CELL HARVESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL HARVESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CELL HARVESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL HARVESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CELL HARVESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL HARVESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CELL HARVESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL HARVESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CELL HARVESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL HARVESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CELL HARVESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL HARVESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CELL HARVESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL HARVESTING MARKET SIZE, BY PRECLINICAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CELL HARVESTING MARKET SIZE, BY PRECLINICAL SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL HARVESTING MARKET SIZE, BY PRECLINICAL SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CELL HARVESTING MARKET SIZE, BY PRECLINICAL SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL HARVESTING MARKET SIZE, BY PRECLINICAL SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CELL HARVESTING MARKET SIZE, BY PRECLINICAL SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL HARVESTING MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CELL HARVESTING MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL HARVESTING MARKET SIZE, BY TOXICOLOGY STUDIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CELL HARVESTING MARKET SIZE, BY TOXICOLOGY STUDIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL HARVESTING MARKET SIZE, BY TOXICOLOGY STUDIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CELL HARVESTING MARKET SIZE, BY TOXICOLOGY STUDIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL HARVESTING MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CELL HARVESTING MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL HARVESTING MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CELL HARVESTING MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL HARVESTING MARKET SIZE, BY REGENERATIVE MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CELL HARVESTING MARKET SIZE, BY REGENERATIVE MEDICINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL HARVESTING MARKET SIZE, BY REGENERATIVE MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CELL HARVESTING MARKET SIZE, BY REGENERATIVE MEDICINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL HARVESTING MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CELL HARVESTING MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL HARVESTING MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CELL HARVESTING MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL HARVESTING MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CELL HARVESTING MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL HARVESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CELL HARVESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL HARVESTING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CELL HARVESTING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL HARVESTING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CELL HARVESTING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL HARVESTING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CELL HARVESTING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELL HARVESTING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CELL HARVESTING MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELL HARVESTING MARKET SIZE, BY BUFFERS & SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CELL HARVESTING MARKET SIZE, BY BUFFERS & SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL HARVESTING MARKET SIZE, BY BUFFERS & SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CELL HARVESTING MARKET SIZE, BY BUFFERS & SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL HARVESTING MARKET SIZE, BY BUFFERS & SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CELL HARVESTING MARKET SIZE, BY BUFFERS & SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELL HARVESTING MARKET SIZE, BY CULTURE MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CELL HARVESTING MARKET SIZE, BY CULTURE MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL HARVESTING MARKET SIZE, BY CULTURE MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CELL HARVESTING MARKET SIZE, BY CULTURE MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL HARVESTING MARKET SIZE, BY CULTURE MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CELL HARVESTING MARKET SIZE, BY CULTURE MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL HARVESTING MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CELL HARVESTING MARKET SIZE, BY ENZYMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL HARVESTING MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CELL HARVESTING MARKET SIZE, BY ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL HARVESTING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CELL HARVESTING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELL HARVESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CELL HARVESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CELL HARVESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CELL HARVESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CELL HARVESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CELL HARVESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELL HARVESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CELL HARVESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CELL HARVESTING MARKET SIZE, BY AUTOMATED CELL COUNTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CELL HARVESTING MARKET SIZE, BY AUTOMATED CELL COUNTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CELL HARVESTING MARKET SIZE, BY AUTOMATED CELL COUNTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CELL HARVESTING MARKET SIZE, BY AUTOMATED CELL COUNTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CELL HARVESTING MARKET SIZE, BY AUTOMATED CELL COUNTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CELL HARVESTING MARKET SIZE, BY AUTOMATED CELL COUNTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOREACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOREACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOREACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOREACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOREACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CELL HARVESTING MARKET SIZE, BY CENTRIFUGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CELL HARVESTING MARKET SIZE, BY CENTRIFUGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CELL HARVESTING MARKET SIZE, BY CENTRIFUGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CELL HARVESTING MARKET SIZE, BY CENTRIFUGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CELL HARVESTING MARKET SIZE, BY CENTRIFUGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CELL HARVESTING MARKET SIZE, BY CENTRIFUGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL LINES, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL LINES, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL LINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL LINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL LINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL LINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL LINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CELL HARVESTING MARKET SIZE, BY CELL LINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CELL HARVESTING MARKET SIZE, BY CHO CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CELL HARVESTING MARKET SIZE, BY CHO CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CELL HARVESTING MARKET SIZE, BY CHO CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CELL HARVESTING MARKET SIZE, BY CHO CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CELL HARVESTING MARKET SIZE, BY CHO CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CELL HARVESTING MARKET SIZE, BY CHO CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CELL HARVESTING MARKET SIZE, BY HEK293 CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CELL HARVESTING MARKET SIZE, BY HEK293 CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CELL HARVESTING MARKET SIZE, BY HEK293 CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CELL HARVESTING MARKET SIZE, BY HEK293 CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CELL HARVESTING MARKET SIZE, BY HEK293 CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CELL HARVESTING MARKET SIZE, BY HEK293 CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CELL HARVESTING MARKET SIZE, BY HELA CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CELL HARVESTING MARKET SIZE, BY HELA CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CELL HARVESTING MARKET SIZE, BY HELA CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CELL HARVESTING MARKET SIZE, BY HELA CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CELL HARVESTING MARKET SIZE, BY HELA CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CELL HARVESTING MARKET SIZE, BY HELA CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CELL HARVESTING MARKET SIZE, BY IMMUNE CELLS, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CELL HARVESTING MARKET SIZE, BY IMMUNE CELLS, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CELL HARVESTING MARKET SIZE, BY IMMUNE CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CELL HARVESTING MARKET SIZE, BY IMMUNE CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CELL HARVESTING MARKET SIZE, BY IMMUNE CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CELL HARVESTING MARKET SIZE, BY IMMUNE CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CELL HARVESTING MARKET SIZE, BY IMMUNE CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CELL HARVESTING MARKET SIZE, BY IMMUNE CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CELL HARVESTING MARKET SIZE, BY B CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CELL HARVESTING MARKET SIZE, BY B CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CELL HARVESTING MARKET SIZE, BY B CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CELL HARVESTING MARKET SIZE, BY B CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CELL HARVESTING MARKET SIZE, BY B CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CELL HARVESTING MARKET SIZE, BY B CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CELL HARVESTING MARKET SIZE, BY T CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CELL HARVESTING MARKET SIZE, BY T CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CELL HARVESTING MARKET SIZE, BY T CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CELL HARVESTING MARKET SIZE, BY T CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CELL HARVESTING MARKET SIZE, BY T CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CELL HARVESTING MARKET SIZE, BY T CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CELL HARVESTING MARKET SIZE, BY PRIMARY CELLS, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CELL HARVESTING MARKET SIZE, BY PRIMARY CELLS, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CELL HARVESTING MARKET SIZE, BY PRIMARY CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CELL HARVESTING MARKET SIZE, BY PRIMARY CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CELL HARVESTING MARKET SIZE, BY PRIMARY CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CELL HARVESTING MARKET SIZE, BY PRIMARY CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CELL HARVESTING MARKET SIZE, BY PRIMARY CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CELL HARVESTING MARKET SIZE, BY PRIMARY CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CELL HARVESTING MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CELL HARVESTING MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CELL HARVESTING MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CELL HARVESTING MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CELL HARVESTING MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CELL HARVESTING MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CELL HARVESTING MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CELL HARVESTING MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CELL HARVESTING MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CELL HARVESTING MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CELL HARVESTING MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CELL HARVESTING MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CELL HARVESTING MARKET SIZE, BY PERIPHERAL BLOOD MONONUCLEAR CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CELL HARVESTING MARKET SIZE, BY PERIPHERAL BLOOD MONONUCLEAR CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CELL HARVESTING MARKET SIZE, BY PERIPHERAL BLOOD MONONUCLEAR CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CELL HARVESTING MARKET SIZE, BY PERIPHERAL BLOOD MONONUCLEAR CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CELL HARVESTING MARKET SIZE, BY PERIPHERAL BLOOD MONONUCLEAR CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CELL HARVESTING MARKET SIZE, BY PERIPHERAL BLOOD MONONUCLEAR CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CELL HARVESTING MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CELL HARVESTING MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CELL HARVESTING MARKET SIZE, BY STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CELL HARVESTING MARKET SIZE, BY STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CELL HARVESTING MARKET SIZE, BY STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CELL HARVESTING MARKET SIZE, BY STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CELL HARVESTING MARKET SIZE, BY STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CELL HARVESTING MARKET SIZE, BY STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CELL HARVESTING MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CELL HARVESTING MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CELL HARVESTING MARKET SIZE, BY EMBRYONIC STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CELL HARVESTING MARKET SIZE, BY EMBRYONIC STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CELL HARVESTING MARKET SIZE, BY EMBRYONIC STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CELL HARVESTING MARKET SIZE, BY EMBRYONIC STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CELL HARVESTING MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CELL HARVESTING MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CELL HARVESTING MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CELL HARVESTING MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CELL HARVESTING MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CELL HARVESTING MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CELL HARVESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CELL HARVESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CELL HARVESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CELL HARVESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CELL HARVESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CELL HARVESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CELL HARVESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CELL HARVESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOTECH & PHARMA COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOTECH & PHARMA COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOTECH & PHARMA COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOTECH & PHARMA COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOTECH & PHARMA COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CELL HARVESTING MARKET SIZE, BY BIOTECH & PHARMA COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CELL HARVESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CELL HARVESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CELL HARVESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CELL HARVESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL CELL HARVESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL CELL HARVESTING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL CELL HARVESTING MARKET SIZE, BY HOSPITALS & CLINICAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL CELL HARVESTING MARKET SIZE, BY HOSPITALS & CLINICAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL CELL HARVESTING MARKET SIZE, BY HOSPITALS & CLINICAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL CELL HARVESTING MARKET SIZE, BY HOSPITALS & CLINICAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL CELL HARVESTING MARKET SIZE, BY HOSPITALS & CLINICAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL CELL HARVESTING MARKET SIZE, BY HOSPITALS & CLINICAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL CELL HARVESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL CELL HARVESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS CELL HARVESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS CELL HARVESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS CELL HARVESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS CELL HARVESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS CELL HARVESTING MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS CELL HARVESTING MARKET SIZE, BY CELL BANKING, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS CELL HARVESTING MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS CELL HARVESTING MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS CELL HARVESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS CELL HARVESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS CELL HARVESTING MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS CELL HARVESTING MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS CELL HARVESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS CELL HARVESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS CELL HARVESTING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS CELL HARVESTING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS CELL HARVESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS CELL HARVESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS CELL HARVESTING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS CELL HARVESTING MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS CELL HARVESTING MARKET SIZE, BY CELL LINES, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS CELL HARVESTING MARKET SIZE, BY CELL LINES, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS CELL HARVESTING MARKET SIZE, BY IMMUNE CELLS, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS CELL HARVESTING MARKET SIZE, BY IMMUNE CELLS, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS CELL HARVESTING MARKET SIZE, BY PRIMARY CELLS, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS CELL HARVESTING MARKET SIZE, BY PRIMARY CELLS, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS CELL HARVESTING MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS CELL HARVESTING MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS CELL HARVESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS CELL HARVESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY CELL BANKING, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY CONSUMABLES & REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY CELL LINES, 2018-2024 (USD MILLION)
  • TABLE 320. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY CELL LINES, 2025-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY IMMUNE CELLS, 2018-2024 (USD MILLION)
  • TABLE 322. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY IMMUNE CELLS, 2025-2032 (USD MILLION)
  • TABLE 323. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY PRIMARY CELLS, 2018-2024 (USD MILLION)
  • TABLE 324. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY PRIMARY CELLS, 2025-2032 (USD MILLION)
  • TABLE 325. NORTH AMERICA CELL HARVESTING MARKET SIZE, BY STEM CELL